Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Immune Pharmaceuticals to Take Over Epicept

Published: Friday, November 09, 2012
Last Updated: Friday, November 09, 2012
Bookmark and Share
The merged company will develop antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer.

Immune Phamaceuticals Ltd. is taking over EpiCept Corporation in share swap deal. The merged company, Immune Pharmaceuticals Inc., will develop antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. The merger is due to close in the first quarter of 2013.

Immune Pharmaceuticals shareholders will own 77.5% of the merged company, and EpiCept shareholders will own 22.5%. The merged company will be headquartered in Herzliya Pituach and in Tarrytown, New York, and will have research laboratories in Rehovot. Immune Pharmaceuticals founder and CEO Dr. Daniel Teper will become the chairman and CEO of the merged company, and Dr. David Sidransky will become vice chairman.

Immune’s lead product candidate, bertilimumab, is a full human monoclonal antibody for the treatment of inflammatory diseases. It is undergoing a Phase II clinical trial for the treatment of ulcerative colitis. The merged company's oncology products will include Immune’s NanomAbs, a new generation of antibody drug conjugates, and EpiCept’s AmiKet, which is undergoing a Phase III clinical trial for the treatment of chemotherapy-induced neuropathic pain and post-herpetic neuralgia.

Teper and EpiCept interim president and CEO Robert Cook said in a statement, "This transaction will create a publicly traded specialty biopharmaceutical company with a portfolio of four clinical-stage drug candidates for the treatment of inflammatory diseases and cancer. Immune's bertilimumab, a first in class monoclonal antibody, is being evaluated clinically to address unmet medical needs in multiple severe disease indications. EpiCept's Amiket has clinical data in over 1,600 patients in various neuropathies, Fast Track designation and Phase III Special Protocol Assistance from the US Food and Drug Administration as well as a defined clinical path through the European Medicines Agency for the treatment of chemotherapy induced neuropathic pain."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immune Pharma Announces Exclusive License
New technology will allow for the development of innovative drug candidates targeting immune checkpoints.
Monday, January 04, 2016
Immune Pharmaceuticals Licenses a Novel Bispecific Antibody Technology
New technology will allow for the development of innovative drug candidates targeting immune checkpoints.
Tuesday, December 29, 2015
Immune Initiates Bertilimumab Phase II Clinical Trial in Ulcerative Colitis
Bertilimumab targets eotaxin-1, a chemokine over-expressed in ulcerative colitis patients.
Friday, February 22, 2013
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Itchy Inflammation Of Mosquito Bites Helps Viruses Replicate
The itchy swelling that appears at the site of a mosquito bite isn't just an irritating nuisance - it also makes viral infections spread by the insects far worse, new research has found.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Revealing T-Cells in Action
Salk scientists show how T-cell receptors reposition during an immune response, revealing more on how the immune system is regulated.
Impact of Antibiotic Treatment on the Infant Gut Microbiome
Study shows that antibiotic treatment reduces stability and diversity of microbial population in the first three years of life.
Viruses Hack Their Host's Genome with CRISPR
A virus that infects major freshwater bacteria appears to use stolen bits of immune system DNA to highjack their hosts’ immune response.
Reclaiming The Immune System's Assault On Tumors
EPFL study shows a way to reclaim corrupted immune cells.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!